US-Israel health partnership funds biotech innovation—but who pays?

What it does

This bill establishes a formal US-Israel bilateral research program called the BIRD Health Program, administered by the existing BIRD Foundation, to jointly develop and commercialize healthcare technologies including medical devices, pharmaceuticals, diagnostics, and digital health solutions. The program authorizes $10 million per year from 2026–2032, with joint governance by the US Department of Health and Human Services and Israel's Ministry of Health, and requires annual reporting to Congress on funded projects and their economic impact.

Why we flagged it

The bill's core function is establishing a formal bilateral research and commercialization program between the US and Israel in healthcare technologies. It is neither deregulation nor a tax provision, but rather a structured international collaboration framework with dedicated funding.

What the text implies

• The bill prioritizes 'commercialization and deployment' and 'commercial potential' as selection criteria, but does not mandate that resulting treatments be affordable, accessible, or available to US patients at reasonable cost—only that they be developed and sold.
• Joint governance with Israel's Ministry of Health and administration through the BIRD Foundation (a private entity) may create opacity around how US taxpayer funds are allocated and whether projects prioritize US public health needs or bilateral economic interests.
• The program explicitly supports 'biological product manufacturing' and 'supply chain resilience,' which may benefit pharmaceutical and biotech companies more than patients if it subsidizes private manufacturing without public ownership or pricing controls.
• Data-sharing provisions ('framework for sharing health data for research purposes with the Ministry of Health of Israel') lack explicit privacy safeguards or congressional oversight of what health data is shared and under what terms.

Who it affects

The bill may accelerate development of innovative healthcare technologies and treatments that could benefit patients, particularly in areas like vaccines, diagnostics, and rare diseases. However, the mechanism for ensuring public benefit (pricing, access, affordability) is absent; the program prioritizes commercialization and economic impact without explicit safeguards that resulting treatments will be affordable or accessible to ordinary Americans.

Who stands to gain

• pharmaceutical companies
• biotechnology firms
• medical device manufacturers
• digital health startups
• contract research organizations

Named in the bill

BIRD Foundation (Binational Industrial Research and Development Foundation), Department of Health and Human Services (HHS), Department of Commerce (DOC), Ministry of Health of Israel, CAH (Cardinal Health Inc., semantic affinity)

Where it stands

8 cosponsors: 4 Democrats, 4 Republicans.

• Jul 16, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 16, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,046,963 in lobbying spend. A filing names 42 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Randy Weber, the sponsor, reported $473,900 in PAC receipts in the 2026 cycle.

• American Israel Public Affairs Committee — $1,784,900 on 2 filings
• Ut Southwestern Medical Center — $142,063 on 1 filing
• Hadassah, the Women's Zionist Organization of America, Inc. — $120,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.